Citations

Clear

159 citation(s) found for "Soto, S R".

Novel wounded porcine skin ex vivo methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa infection models
Kies, Paige , Gades, Naomi M , Tian, Aileen , Soto, Mya L, Mandrekar, Jay , Garcia, Elijah , Patel, Robin

Mayo Clinic

Infection and Immunity | November 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1128/iai.00489-26 | PMID 43037414 Get It

ABSTRACT Chronic wounds are a growing challenge in clinical practice and can be associated with infection by antimicrobial-resistant bacteria. With increasing demand for pathophysiology research and therapeutic technology development, biologically relevant platforms like infected swine skin explants are used; however, explants are not typically studied in conjunction with normal microbiota, which recapitulates the clinical scenario. The current study generated 1- and 8-cm diameter wounded swine skin explants from shaved, sanitized swine skin harvested immediately after euthanasia. Tissue morphology was evaluated over 9 days using a custom histological grading scale and growth dynamics of skin microbiota monitored. Explant viability decreased after 3 days in association with a peak in normal microbiota of varying diversity. Stable co-colonization of wound beds with clinical Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus isolates alongside microbiota over 3 days was demonstrated. In summary, the presented 1- and 8-cm explant models maintain normal microbiota and are suitable for microbiome and/or wound infection treatment or prevention studies.
Safety and Feasibility of Reduced-Frequency Dosing of Axatilimab in Patients Treated in the AGAVE-201 Study
Farhadfar, Nosha , Soto, Maria Sola, Chhabra, Saurabh , Bhatt, Valkal, Andersen, Emily Helen, Xue, Zhenyi , DeFilipp, Zachariah

Mayo Clinic

Blood Advances | October 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026021323 | PMID 42913434 Get It

Measuring Symptom Severity and Health-Related Quality-of-Life with Hemorrhoid Treatments: Systematic Review
Soto, Marquise, Srinivasan, Vamshek, Perry, William, Shah, Eric D.

Mayo Clinic

Diseases of the Colon & Rectum | September 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/dcr.0000000000004429 | PMID 42775535 Get It

BACKGROUND: Hemorrhoids are common and relief anchors on symptom improvement. Despite several available treatment options, the optimal patient-reported outcome measure for contemporary clinical trials is not established. OBJECTIVE: We aimed to systematically assess patient-reported outcome measures that measure hemorrhoid symptom severity and/or health-related quality of life. DATA SOURCES: A systematic review was performed using PubMed and Embase (1980-2025). STUDY SELECTION: Prospective development/validation studies evaluating patient-reported outcome measures relevant to hemorrhoidal disease. MAIN OUTCOME MEASURES: Patient-reported outcome measures were evaluated on key measurement properties of reliability, internal consistency, construct validity, and responsiveness according to COSMIN v2.0 criteria. RESULTS: Of the 1,266 total studies reviewed, nine patient-reported outcome measures were identified: seven measure symptom severity and six measure health-related quality-of-life. Three demonstrated reliability, internal consistency, construct validity, and responsiveness. The Patient Reported Outcome Measure-Haemorrhoidal Impact And Satisfaction Score comprehensively measures symptom severity, health-related quality-of-life, and treatment satisfaction. The Hemorrhoidal Disease Symptom Score classifies patients with high or low symptom load, and when used in combination with Short Health Scale-Hemorrhoidal Disease, also measures impact on health-related quality of life. LIMITATIONS: Preference toward specific measures may differ between clinical trials and clinical practice. CONCLUSIONS: We identify two viable patient-reported outcome measures for use in future clinical trials that evaluate hemorrhoid interventions.
The VPS35 p.A320V variant segregates with Parkinson's disease in a pesticide-exposed family
Glendinning, S. G. , Gonzalez, Jose Matias Arbelo , Díaz-Feliz, Lola , Zamora, Rocio Malo de Molina, Sanchez-Reyes, Alexia Teresa , Su, Kimmy , Cole, D. J., Hsieh, F. , Ross, Owen A. , (GP2), Global Parkinson's Genetics Program, Initiative, Veterans Parkinson's Disease Genetics, Ross, Owen A , Glendinning, Sophie , Zamor, Rocio Malo de Molina, Gomes, Sara , Soto‐Beasley, Alexandra I. , Wszołek, Zbigniew K. , Kim, Han‐Joon , Shin, Jung Hwan , Lim, Shen‐Yang , Tan, Ai Huey , Ahmad‐Annuar, Azlina , Tay, Yi Wen , Kleinz, Teresa , Klein, Christine , Alessi, Dario R. , Zimprich, Alexander , Pástor, Pau , Sammler, Esther , (GP2), Global Parkinson s Genetic Program, Zabetian, Cyrus P. , Lorenzo‐Betancor, Oswaldo

Mayo Clinic

No container title available | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.21.26358613 Get It

Background. The VPS35 p.D620N variant causes autosomal dominant Parkinson's disease (PD) and has been shown to activate the LRRK2 kinase pathway, resulting in increased Rab substrate phosphorylation in peripheral immune cells and elevated urinary bis(monoacylglycero)phosphate (BMP) levels. Recently, a VPS35 variant of unknown significance (c.959C>T; p.A320V) was described in two late-onset sporadic PD patients. Methods. We ascertained a family from the Canary Islands in which six siblings were chronically exposed to high doses of pesticides. Three siblings developed levodopa-responsive, akinetic-rigid PD, while the other three remained unaffected. Whole-exome sequencing was performed in the three affected siblings. The frequency of the resulting candidate variant was assessed in 23,327 PD patients and 9,235 controls from four independent cohorts. Members of this pedigree and unrelated controls were assessed for LRRK2 kinase activity in monocytes and neutrophils and BMP levels in urine. Results. The three affected siblings were all heterozygous for p.A320V, whereas the three unaffected siblings did not carry the variant. In the combined PD case-control cohort, p.A320V was identified in six patients and one control. However, unlike p.D620N, heterozygous carrier status for p.A320V was not associated with increased LRRK2 kinase activity or elevated urine BMP levels. Conclusions. While VPS35 p.A320V co-segregated with PD in this family, it did not exhibit the characteristic LRRK2-associated biomarker signature observed in VPS35 p.D620N carriers. It is possible that p.A320V exerts a subtle effect on VPS35 function that was not captured by the assays performed and that chronic pesticide exposure contributed to disease penetrance in this pedigree.
Glomerular-Targeted Delivery of Low-Dose Prednisolone Attenuates Established Lupus Nephritis in MRL/lpr Mice
Williams, Kristof , Agyekum, Georgina , Patne, Akshata, Markoutsa, Eleni, Chellappan, David Raj, Hall, Nathan, Tian, Zhi , Soto, Nohely Hernandez, Cuadrao, Sebastian, Lozonschi, Isabella, Fu, Liying, Haight, Lilliana, Sharma, Rahul, Mohapatra, Subhra, Wang, Lei, Liu, Ruisheng, Fu, Liying, Sharma, Rahul, Wang, Lei , Mohapatra, Shyam S. , Liu, Ruisheng

Mayo Clinic

No container title available | August 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.01.742194 Get It

Abstract Background Lupus nephritis remains a major cause of chronic kidney disease and kidney failure in systemic lupus erythematosus. Glucocorticoids are central to treatment but are limited by systemic toxicity. We evaluated whether a previously characterized collagen IV α3-targeted liposomal nanoparticle formulation carrying low-dose prednisolone could attenuate established lupus nephritis in MRL/lpr mice. Methods Female MRL/lpr mice with disease present at treatment initiation and C57BL/6J control mice received saline or collagen IV α3-targeted prednisolone-loaded nanoparticles (Col4-α3-Pred-NPs). Renal outcomes were assessed by longitudinal proteinuria, glomerular filtration rate (GFR), survival, kidney histopathology, renal IgG and C3d deposition, dUTP/TUNEL-associated injury staining, and renal cytokine/chemokine profiling. Body weight, food and water intake, and blood glucose were monitored as measures of general condition and preliminary tolerability. Results Col4-α3-Pred-NPs improved survival in MRL/lpr mice, reduced cumulative proteinuria burden, and attenuated terminal GFR decline compared with saline-treated MRL/lpr controls. Treatment reduced glomerular and tubulointerstitial injury, lowered composite EGTI histopathology scores, decreased terminal kidney enlargement, reduced glomerular IgG deposition and renal dUTP-positive injury signals, and reduced renal signals for IL-28A/B, IL-7, PD-ECGF, IL-11, CCL6/C10, and IL-15. C3d deposition was not significantly altered. Nanoparticle treatment was not associated with sustained treatment-related increases in blood glucose or body-weight loss during the measured study period. Conclusions Collagen IV α3-targeted liposomal delivery of low-dose prednisolone attenuated established lupus nephritis in MRL/lpr mice and improved renal structural, functional, inflammatory, and survival outcomes. These findings support further evaluation of glomerulus-targeted nanotherapy as a potential strategy to improve the precision and therapeutic index of glucocorticoid treatment in lupus nephritis.
Real-World Practice in Secondary Stroke Prevention Following Embolic Stroke of Undetermined Source
Nour, Hassan Aboul , Siegler, James E. , Thompson, Sean, Glover, Patrick , Daniel, J, Penckofer, Mary , Smith, M A, Yaghi, Shadi , Chen, L, Kerrigan, Deborah , Kirchhoffer, Kaitlyn, Kam, Wayneho , Melkumova, Emiliya , Lineback, Christina , Thottempudi, Neeharika , Heaton, Sharon, Linares, Guillermo , Singh, Eesha , Fernández, Camilo José Albert, Dumitrașcu, Oana , Bowman, Anna, Porto, Camelia Valhuerdi, Chahien, Dalia, Herpich, Franziska , Kang, Jieun , Nelson, Ashley , Shahrivari, Mahan, Khezri, Nicole, Lewis, Skylar, Sathya, Anvitha , Leung, Lester Y. , Eklund, Kelsey , Rojas-Soto, Diana , Nedelcu, Simona , Kasab, Sami Al , Coevering, Russell J. Van, Thon, Jesse , Aboul-Nour, Hassan , Siegler, James E , Thompson, Sean L , Glover, Patrick , Daniel, Jean-Philippe Auguste , Smith, Matthew M , Ro, Jennifer , Chen, Lucia , D'Souza, Marissa , Khasiyev, Farid , Kerrigan, Deborah , Sharma, Richa , Aziz, Yasmin , Kirchhoffer, Kaitlyn , Kam, Wayneho , Melkumova, Emiliya , Sloane, Kelly L , Lineback, Christina M , Thottempudi, Neeharika , Heaton, Sharon , Linares, Guillermo , Almallouhi, Eyad , Stretz, Christoph , Dumitrascu, Oana M , Culbertson, Collin J , Elangovan, Cheran , Bowman, Anna , Valhuerdi Porto, Camelia , Chahien, Dalia , Herpich, Franziska , Farooqui, Mudassir , Kang, Jieun , de Havenon, Adam H , Nelson, Ashley , Shahrivari, Mahan , Stamm, Brian , Khezri, Nicole , Lewis, Skylar , Sathya, Anvitha , Leung, Lester Y , Eklund, Kelsey , Rojas-Soto, Diana , Nedelcu, Simona , Al Kasab, Sami , Thon, Jesse , Jillella, Dinesh V , Nahab, Fadi B , Yaghi, Shadi , Penckofer, Mary , D’Souza, Marissa , Khasiyev, Farid , Sharma, Richa , Aziz, Yasmin , Almallouhi, Eyad , Stretz, Christoph , Elangovan, Cheran , Havenon, Adam de , Stamm, Brian , Coevering, Russell J. Van , Jillella, Dinesh

Mayo Clinic

Neurology Clinical Practice | July 10, 2026 | Volume: 16 | Issue: 4 | Pages: No page available

10.1212/cpj.0000000000200631 | PMID 42430672 Get It

Evaluating MAPT p.A152T as a risk factor for the 3R tauopathy Pick’s disease
Tamvaka, Nicole , Scotton, William J. , Lilley, Meredith T. , Shoai, Maryam , Gavrielatos, Marios , HECKMAN, M, Roemer, Shanu F, Baker, Matthew C, Rademakers, Rosa, Hardy, John , Cook, Casey , Lashley, Tammaryn , Jaunmuktane, Zane, Mok, Kin, Revesz, Tamas, Christopher, Elizabeth, DeTure, Michael, Koga, Shunsuke, Graff-Radford, Neill R, Boeve, Bradley F, Josephs, Keith A. , Petersen, Ronald C, Whitwell, Jennifer , Duara, Ranjan, Lyons, Kelly E, Miller, Bruce, Schlereth, Athena, Spina, Salvatore, Irwin, David J, Wolk, David A, Suh, EunRan, Deerlin, Vivianna M Van, Lee, Edward B, Frosch, Matthew P. , Molina-Porcel, Laura, Aldecoa, Iban, Balasa, Mircea, Borrego-Ecija, Sergi, Sanchez-Valle, Raquel, Gascón‐Bayarri, Jordi , Sanz-Cartagena, Pilar , Huélamo, Rosa Maria de Eugenio, Gefen, Tamar, Castellani, Rudolph J, Rogalskı, Emily , Weıntraub, Sandra , Bieniek, Kevin F, Zhu, Xiongwei, Redding-Ochoa, Javier, Troncoso, Juan C. , Ghetti, Bernardino, Newell, Kathy L. , Jacobsen, Max, Roncaroli, Federico, Jones, Matthew, Richardson, Anna, Snowden, Julie, Allinson, Kieren, Beach, Thomas G, Teich, Andrew F, Flowers, Xena, Heaps, Allison C, Leskinen, Sandra , Keith, Julia , Masellis, Mario, King, Andrew, Sarraj, Safa-Al, Hodges, John R. , Gearing, Marla , Roeber, Sigrun, Attems, Johannes, Boluda, Susana , Seilhean, Danielle, Ber, Isabelle Le, Turbant-Leclere, Sabrina, Mackenzie, Ian R. , Sieben, Anne, Cras, Patrick , Vil, Bart B De, Deyn, P P De, Keene, C Dirk, Latimer, Caitlin S. , Schantz, Aimee, Bird, Thomas D, Haroutunian, Vahram, Purohit, Dushyant, Rissman, Robert, Cykowski, Matthew D. , Wang, Shih-Hsiu J, Ervin, John F. , Nennesmo, Inger , Nagra, Rashed M. , Riehl, James, Kovacs, Gabor G, Neumann, Manuela, Ang, Lee-Cyn, Cunha, Cristina, Blauwendraat, Cornelis , Nalls, Mike A., Singleton, Andrew B, Perrin, Richard J. , Chaffee, Anne M, Scotton, William , Murray, Melissa E , Dickson, Dennis W , Ross, Owen A , Hardy, John , Shoai, Maryam , Lashley, Tammaryn , Heckman, Michael G. , Soto‐Beasley, Alexandra I. , Roemer, Shanu F. , Rademakers, Rosa , Murray, Melissa E. , Dickson, Dennis W. , Rohrer, Jonathan D. , Ross, Owen A. , Valentino, Rebecca R. , Macpherson, Hannah L. , Warner, Thomas T. , Jaunmuktane, Zane , Martínez-Carrasco, Alejandro , Revesz, Tamas, DeTure, Michael , Koga, Shunsuke , Graff‐Radford, Neill R. , Boeve, Bradley F. , Petersen, Ronald C. , Duara, Ranjan, Pahwa, Rajesh , Grinberg, Lea T. , Seeley, William W. , Miller, Bruce L , Spina, Salvatore , Suh, EunRan , Deerlin, Vivianna M. Van , Connors, Theresa R. , Oakley, Derek H. , Molina‐Porcel, Laura , Aldecoa, Ibán , Balasa, Mircea , Borrego‐Écija, Sergi , Sánchez‐Valle, Raquel , Piñol‐Ripoll, Gerard , Gelpí, Ellen , Gefen, Tamar , Castellani, Rudolph J. , Flanagan, Margaret E. , Schneider, Julie A. , Bieniek, Kevin F. , Redding‐Ochoa, Javier , Chang, Koping , Prokop, Stefan , Ghetti, Bernardino, Robinson, Andrew , Roncaroli, Federico , Kobylecki, Christopher , Richardson, Anna, Rowe, James B. , Quaegebeur, Annelies , Allinson, Kieren Simon James, Beach, Thomas G. , Serrano, Geidy E. , Teich, Andrew F. , Black, Sandra E. , Masellis, Mario, Troakes, Claire , Halliday, Glenda M. , Kril, Jillian J. , Kwok, John B. , Piguet, Olivier , Morris, Christopher M. , Thomas, Alan , White, Charles L. , Evers, Bret M. , Mechawar, Naguib , Seilhean, Danielle , Ber, Isabelle Le , Leclère-Turbant, Sabrina, Vil, Bart De , Deyn, Peter Paul De , Keene, C Dirk, Haroutunian, Vahram , Purohit, Dushyant P. , Walker, Jamie M. , Rissman, Robert A. , McLean, Catriona , Graff, Caroline , Riehl, James R. , Giaccone, Giorgio , Neumann, Manuela , Finger, Elizabeth C. , Carvalho, Agostinho , Morris, Huw R. , Singleton, Andrew B, Vitale, Dan , Chaffee, Ann, Wszołek, Zbigniew K.

Mayo Clinic

Brain Communications | July 9, 2026 | Volume: 8 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcag266 | PMID 42553595 Get It

Abstract Genetic studies have significantly advanced our understanding of tauopathies, yet the genetic aetiology of Pick’s disease, a rare 3-Repeat tauopathy, remains unclear. The MAPT p.A152T variant has been identified as a risk factor for Alzheimer’s disease and progressive supranuclear palsy, but its role in Pick’s disease is unknown. In this study, we examined the prevalence of MAPT p.A152T in the largest series of neuropathologically confirmed Pick’s disease cases to date (n = 401). Through genotyping, we identified a single mutation carrier in the Pick’s disease cohort (minor allele frequency = 0.12%). We previously reported MAPT p.A152T at a 0.20% frequency in healthy controls (n = 2456), suggesting that it does not associate with 3-Repeat tauopathy risk. To further investigate the effect of the variant on MAPT transcript expression, we used bulk RNA sequencing in Alzheimer’s disease and progressive supranuclear palsy A152T mutation carriers. We did not detect significant differences in 4-Repeat tau levels, though preliminary trends may indicate more nuanced effects that need to be examined with long-read sequencing in a larger series. Overall, our study suggests that MAPT p.A152T does not increase Pick’s disease risk and may instead be linked to 4-Repeat or mixed tau pathologies, warranting further functional investigation.
Longitudinal Dynamics of Polyglutamine‐Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3
Bartfield, Jordan, Milanowski, L, Jansen‐West, Karen , Al‐Shaikh, Rana Hanna , Chmiela, Tomasz , Dunmore, Judith A. , Gorcenco, Sorina , Puschman, Andreas, Lemos, João, Januario, C, Ledoux, Mark S., Onodera, O, Aiba, I, Pfeiffer, Ronald F., Paulson, Henry, McLoughlin, Hayley S., Teive, Helio A.G., Soto-Piña, Alexandra E., Uitti, Ryan J., Strongosky, Audrey, Petrucelli, L, Paulson, Henry L. , Milanowski, Łukasz , Dunmore, Judith A , Gorcenco, Sorina , Friedman, Joseph H. , Sławek, Jarosław , Wszolek, Z.K. , Chmiela, Tomasz , Paulson, Henry L , Milanowski, Łukasz M , Gendron, Tania F. , Lemos, João , Januário, Cristina , Onodera, Osamu , Aiba, Ikuko , Pfeiffer, Ronald F. , McLoughlin, Hayley S. , Dulski, Jarosław , Sławek, Jarosław , Teive, Hélio Afonso Ghizoni , Soto‐Piña, Alexandra Estela , Uitti, Ryan J. , Strongosky, Audrey , Prudencio, Mercedes , Wszołek, Zbigniew K.

Mayo Clinic

Movement Disorders | July 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/mds.70411 | PMID 42381263 Get It

Abstract Background Spinocerebellar ataxia type 3 (SCA3), the most common autosomal dominant ataxia, is driven by the accumulation of polyglutamine‐expanded (polyQ) ATXN3 proteins. While promising as biomarkers, their longitudinal trajectories across multiple biofluids remain poorly defined. Objectives To quantify polyQ ATXN3 levels in cerebrospinal fluid (CSF), plasma, and urine within a comprehensive cohort, utilizing serial measurements to map protein dynamics. Methods We employed a validated immunoassay to quantify polyQ ATXN3 in 97 symptomatic and 13 presymptomatic SCA3 patients, correlating levels with clinical features, ancestry, disease status, and longitudinal progression. Results Asian participants exhibited lower plasma but elevated urinary polyQ ATXN3 levels relative to other ancestries. While CSF levels were higher in symptomatic patients at baseline, they showed a significant longitudinal decline. Conclusions PolyQ ATXN3 is a viable multi‐biofluid biomarker. Declining CSF levels likely reflect neurodegeneration, supporting its role in tracking progression and emphasizing the need for ancestry‐based adjustment in trials. © 2026 International Parkinson and Movement Disorder Society.